Bildkälla: Stockfoto

Cantargia: Comments on the Recent Opposition, Deal and CAN10 News - Redeye

Redeye has looked into the opposition against Cantargia's patent EP3293202 earlier this month and finds a common denominator in the recently announced deal for an IL1RAP antibody, which is a potential competitor to CAN10.

Redeye has looked into the opposition against Cantargia's patent EP3293202 earlier this month and finds a common denominator in the recently announced deal for an IL1RAP antibody, which is a potential competitor to CAN10.
Börsvärldens nyhetsbrev
ANNONSER